Table 2.
Baseline endocrine parameters in the patients and healthy subjects
| Variable | Patients (N = 11) | Healthy subjects (N = 10) | P-value (95% CI) |
|---|---|---|---|
| PTH (pmol/l) | 39·9 ± 34·0 (4·0–109·1) | 3·8 ± 1·1 (2·4–6·1) | ND |
| AUC18–24 h(µg h/l) | 2·86 ± 3·91 | 1·09 ± 1·43 | ND |
| IGF-I SD score | –0·6 ± 0·9 (–1·7–0·9) | –1·0 ± 0·9 (–1·8–1·1) | 0·32 (–0·42; 1·24) |
| IGF-I (ng/ml) | 210 ± 76 (117–322) | 178 ± 76 (111–362) | 0·30 (0·85; 1·66) |
| IGFBP-I (ng/ml) | 67·4 ± 42·3 (6·3–126·3) | 26·8 ± 28·3 (6·4–85·4) | 0·03 (1·08; 6·19) |
| IGFBP-III SD score | 2·2 ± 1·5 (–0·6–4·7) | 0·4 ± 0·8 (–1·3–1·5) | 0·004 (0·63; 2·90) |
| IGFBP-III (ng/ml) | 5025 ± 1038 (3067–6654) | 3708 ± 367 (3208–4211) | 0·002 (1·13; 1·57) |
| GHBP (pmol/l) | 993 ± 610 (186–1972) | 1743 ± 512 (1134–2586) | 0·01 (0·27; 0·82) |
| IGF-I/IGFBP-III molar ratio | 0·2 ± 0 (0·1–0·2) | 0·2 ± 0·1 (0·1–0·4) | 0·37 (0·68; 1·16) |
Values are the mean ± SD (range), except for AUC18–24 h(mean ± SD).
PTH, parathyroid hormone; ND, not done; IGF-, insulin-like growth factor-; IGFBP-, insulin-like growth factor binding protein-; SD, standard deviation.